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Introduction
Huntington’s disease (HD) is a progressive neurodegenerative disor-
der for which there is no cure, caused by the expansion of CAG trip-
lets in the huntingtin (HTT) gene. As in other neurodegenerative dis-
eases of genetic origin, symptoms in HD patients have a late onset. 
The reasons for this are not fully known, but might include early acti-
vation of endogenous neuroprotective mechanisms that are not well 
characterized (1). Despite the well-defined genetic cause, the cellu-
lar mechanisms that lead to disease onset and progression remain 
poorly understood. Several interconnected mechanisms that lead to 
altered protein and Ca2+ homeostasis have been proposed (2).
The unfolded protein response (UPR) is an ER process acti-
vated by accumulation of incorrectly folded proteins as well as 
in response to oxidative stress, energy depletion, and disruption 
of Ca2+ homeostasis (3). The UPR is thus a complex program that 
coordinates several signaling pathways. ER stress is sensed by 3 
ER transmembrane receptors, activating transcription factor 6 
(ATF6), inositol-requiring kinase 1 (IRE1), and double-stranded 
RNA-activated protein kinase–like endoplasmic reticulum kinase 
(PERK). In its initial phase, activation of the UPR is protective and 
initiates restoration of protein-folding homeostasis by increasing 
chaperone expression, reducing the protein translation rate, and 
increasing degradation of unfolded proteins. Persistent UPR acti-
vation leads to programmed cell death by mitochondria-mediat-
ed apoptosis or by autophagy (3).
Defective UPR has been implicated in a variety of neurode-
generative and metabolic disorders, including Alzheimer disease, 
Parkinson disease, HD, and prion diseases as well as diabetes and 
vascular diseases (4–6). In most cases, these pathologies are asso-
ciated with chronic activation of PERK, which leads to a sustained 
increase in phospho-eIFα2 levels and the proapoptotic transcrip-
tion factor CCAAT/enhancer-binding protein (CHOP) homolo-
gous protein (7–10). PERK inhibitors are suggested for treatment 
of these diseases (5, 11, 12). In the case of HD, ATF6 processing is 
reduced, with no change in phospho-eIF2, in HD mouse models 
and in HD patients (13).
ER stress is also induced by disrupted Ca2+ homeostasis, which 
recapitulates abnormal changes in various cell functions, includ-
ing deficits in the mitochondrial respiratory chain and severe dis-
ruption of transcription regulation (2). Transcriptome analysis of 
the striatum from distinct HD models and from patients shows 
reduced expression of genes that encode regulatory proteins 
important for Ca2* homeostasis (14, 15). The precise molecular 
mechanisms that link abnormal Ca2+ homeostasis with HD patho-
genesis are nonetheless incompletely understood.
The potassium channel–interacting protein (KChIP) sub-
family of neuronal Ca2+ sensors (NCS) includes multifunctional 
Ca2+-binding proteins with specialized functions through specific 
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Results
Endogenous DREAM levels are reduced in murine HD models and in 
HD patients. To study the functional implications of Ca2+ dereg-
ulation in HD, we focused on the potential role of DREAM, for 
which knockout and dominant active mouse models are avail-
able (27, 28). We analyzed DREAM levels in (a) R6/2 and R6/1 
mice, 2 transgenic models of HD that develop disease symptoms 
shortly after birth or in adulthood, respectively (29); (b) the stria-
tal STHdhQ111/111 cell line derived from knockin mice bearing 111 
CAG repeats in the Htt gene (30); and (c) postmortem brain sam-
ples from HD patients.
In R6 mice, DREAM expression was greatly reduced in the 
striatum (Figure 1, A and B) and in other brain areas including hip-
pocampus and cortex (Supplemental Figure 1; supplemental mate-
rial available online with this article; doi:10.1172/JCI82670DS1). 
In both animal models, this reduction was observed 8 to 9 weeks 
after birth, at a time when disease signs began to appear (R6/2) or 
were not yet apparent (R6/1). Reduced DREAM levels in the stria-
tum were then maintained through the life span in both mouse 
models (Figure 1, A and B). DREAM protein was also reduced in 
heterozygous HdhQ111/7 relative to WT STHdhQ7/7 neurons and 
was virtually absent in homozygous STHdhQ111/111 cells (Figure 
1C). Analysis of striatal samples from HD patients substantiated 
these observations; they showed a reduction in DREAM protein 
compared with that in age-matched controls (Figure 1D).
protein-protein interactions and Ca2+-dependent DNA binding 
(16, 17). Downstream regulatory element antagonist modulator 
(DREAM), also known as KChIP3 or calsenilin (18, 19), is central to 
Ca2+ homeostasis. As a Ca2+-dependent transcriptional repressor, 
DREAM is a master regulator of activity-dependent gene expres-
sion (20) and controls genes important for Ca2+ homeostasis (21, 
22). As an auxiliary protein in the plasma membrane, DREAM 
interacts with and regulates gating of Kv4 potassium channels 
(18), voltage-dependent Ca2+ channels (23, 24), and N-methyl-
d-aspartate receptors (25, 26).
Here, we found that DREAM levels are reduced in mouse 
HD models shortly after birth and well before the appearance 
of locomotor dysfunction. The reduction in DREAM protein 
levels is a neuroprotective response, and chronic administra-
tion of repaglinide, a small molecule that binds DREAM in vitro, 
delayed disease onset, ameliorated locomotor symptoms, and 
prolonged life span in R6/2 mice. DREAM interacts with ATF6 
in a Ca2+-dependent manner, which defines a mechanistic link 
between ER stress conditions and a role for DREAM in HD. 
Moreover, repaglinide competed with the DREAM-ATF6 inter-
action and increased nuclear accumulation of amino terminal 
ATF6 (Nt-ATF6) and ATF6-dependent transcription in stria-
tal neurons in vivo. Our results suggest that an improved UPR 
after ATF6 derepression mediates the positive effect of DREAM 
silencing and repaglinide treatment in HD.
Figure 1. DREAM expression is reduced in murine in vivo and 
in vitro HD models and in HD patients. (A and B) Western blot 
analysis of DREAM protein levels in striatum from R6/1 (A) 
and R6/2 mice (B) and corresponding WT littermates at the 
indicated weeks after birth. Five mice were analyzed in each 
group. Black arrowheads, DREAM immunoreactive band; white 
arrowheads, nonphosphorylated ERK1/2 loading control. After 
densitometric analysis, band intensity ratio vs. loading control 
was normalized to corresponding WT. Significant differences 
compared with WT were calculated using 1-way ANOVA 
(Kruskal-Wallis), followed by Dunnett’s multiple comparisons 
test or Mann-Whitney U test (##P = 0.0079) when comparing 2 
groups (in B, 16 weeks). *P < 0.05; **P < 0.01. (C) Western blot 
analysis of DREAM levels in STHdhQ cells. DREAM-specific 
band intensity is reduced in heterozygous (Q7/111) compared 
with WT (Q7/7) cells and is below the detection limit in homo-
zygous (Q111/111) cells. Black arrowhead, DREAM immunoreactive 
band; white arrowhead, α-tubulin loading control. (D) Western 
blot analysis of DREAM levels in striatal samples from controls 
(n = 5) and HD patients (n = 6). The corresponding brain bank 
code number (BCPA-) is shown below each lane. The DREAM-
specific band (black arrowhead) was scanned, and intensity 
ratio vs. loading control (nonphosphorylated Erk1/2, white 
arrowhead) is shown (right). **P = 0.0019, Mann-Whitney U 
test. Black arrowheads (A–D) indicate the DREAM-specific 
band (Ab 670); white arrowheads show the loading control 
(ERK1/2 in A, B, and D; β-actin in C). 
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tal neurons (Supplemental Figure 4). These results suggest that 
early downregulation of DREAM expression in HD is a defense 
mechanism in R6/2 mice.
DREAM-related neuroprotection was also observed in a 
chemical model of HD based on administration of the mitochon-
drial toxin 3-amino propionic acid (3-NPA) (ref. 31 and Supple-
mental Figure 5). Moreover, we reasoned that if reduced DREAM 
expression in STHdhQ111/111 cells is a neuroprotective mechanism, 
restoration of DREAM levels should sensitize STHdhQ111/111 cells to 
stress. We analyzed cell death in response to stress stimuli in STH-
dhQ111/111 cells after infection with a DREAM- or GFP-expressing 
lentivirus. Basal release of lactate dehydrogenase (LDH) did not 
differ between control and DREAM-overexpressing STHdhQ111/111 
cells. Nonetheless, exposure to the mitochondrial toxins hydro-
gen peroxide (H2O2) (10 μM) or rotenone (100 nM) or to the more 
general toxin staurosporine (5 nM) elicited more LDH release in 
DREAM-infected STHdhQ111/111 cells than in naive or GFP-infect-
ed STHdhQ111/111 cells (Figure 2C).
As these results strongly suggested that DREAM silencing 
is part of an early neuroprotective response in HD, we explored 
DREAM potential as a therapeutic target.
Chronic administration of the DREAM-binding molecule repaglinide 
delays onset and progression of HD symptoms in R6/2 mice. We hypoth-
esized that small molecules able to bind and inhibit DREAM activity 
could be candidates for HD treatment. A literature search identified 
2 reports of molecules that bind to NCS in vitro (32) or modulate for-
mation of the KChIP-Kv4 potassium channel complex (33). The first 
Reduced DREAM expression is a neuroprotective response in 
murine in vivo and in vitro HD models. To determine the func-
tional significance of the early reduction in DREAM expression 
in murine HD models, we modified endogenous DREAM lev-
els in R6 mice crossed with DREAM–/– or transgenic daDREAM 
mice and analyzed the resulting phenotypes. Induced DREAM 
haplodeficiency in R6/2 DREAM+/– mice further reduced 
DREAM levels (Supplemental Figure 2A) and was associated 
with delayed appearance of motor coordination defects. In 
the rotarod test, early symptomatic 11-week-old R6/2 mice 
showed reduced latency to fall, whereas latency to fall in R6/2 
DREAM+/– mice was comparable to that of WT littermates (Fig-
ure 2A). At 16 weeks of age, latency to fall was still longer in 
R6/2 DREAM+/– than in R6/2 mice, although it was lower in 
both genotypes than in WT controls (Figure 2A). We confirmed 
improved locomotion in R6/2 DREAM+/– mice using the foot-
print test (Supplemental Figure 2, B and C).
Induced DREAM haplodeficiency in R6/2 DREAM+/– mice 
also led to a significant increase in life span compared with 
R6/2 mice, whereas DREAM overexpression in R6/1 daDREAM 
mice had the opposite effect and reduced life span compared 
with that of parental R6/1 mice (Figure 2B). A normalized gene 
expression profile in R6/2 DREAM+/– striatum (GEO GSE48104; 
Supplemental Tables 2 and 3) accompanied symptom ameliora-
tion in these mice (Supplemental Figure 3). DREAM haplode-
ficiency nevertheless did not modify progressive loss of body 
weight or the number of HTT-enriched inclusions in R6/2 stria-
Figure 2. Reduced DREAM protein level is 
a neuroprotective response. (A) Latency 
to fall in the rotarod test for mice (n = 
24–30) of the indicated genotypes at 11 and 
16 weeks of age. Significant differences 
between genotypes were found by 2-way 
ANOVA followed by Tukey’s test. **P < 0.01, 
****P < 0.0001 vs. WT; #P < 0.05, ##P < 0.01 
vs. R6/2. (B) Percentage survival (Kaplan-
Meier) of R6/2 (n = 32) and R6/2 DREAM+/– 
(R6/2 DR+/–) (n = 43) (upper panel) or R6/1 
(n = 11) and R6/1 daDREAM mice (n = 9) 
(lower panel). Curves were compared by 
log-rank (Mantel-Cox) test (P < 0.0001). 
(C) Cell death as a percentage of maximum 
LDH released for noninfected STHdhQ111/111 
cells, cells infected with a GFP-expressing 
lentivirus, or cells infected with a DREAM-
GFP–expressing lentivirus. For each group, 
cell death was compared for untreated cells 
vs. cells exposed to vehicle or to the indi-
cated stimuli: H2O2 (10 μM), rotenone (100 
nM), or staurosporine (5 nM). Data (mean 
± SEM) are derived from 3 independent 
experiments in quadruplicate. Statistical 
significance was analyzed by 2-way ANOVA 
followed by Tukey’s test. *P < 0.05,  
****P < 0.0001 vs. basal or vs. GFP groups.
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downstream regulatory element (DRE) sites in vitro and did not 
alter basal expression of DREAM target genes (20) (Supplemental 
Figure 7); repaglinide binding to DREAM thus affects the protein-
protein interaction with Kv4.3 potassium channels, but does not 
modify other activities of DREAM, i.e., its interaction with DNA.
Both repaglinide and glibenclamide are widely used in medical 
practice, which prompted us to explore their therapeutic potential 
in HD. We treated R6/2 mice with repaglinide (2 μg/ml), gliben-
clamide (2 μg/ml), or vehicle (DMSO, 0.2 μl/ml) in drinking water 
shortly after weaning and analyzed changes in HD phenotype.
Repaglinide-treated R6/2 mice showed improved perfor-
mance in the rotarod test. Latency was reduced in DMSO-treated 
R6/2 compared with WT mice at all ages tested, which was sig-
nificant from 10 weeks of age (Figure 4A), the earliest time point 
analyzed. In repaglinide-treated R6/2 mice, however, reduction in 
latency to fall only became significant at 17 weeks of age (Figure 
4A). We observed no effect on motor coordination in WT mice that 
received either DMSO or repaglinide in drinking water. Improved 
locomotion in treated R6/2 mice was paralleled by a reduction 
in striatal atrophy, measured as a reduction in striatal volume by 
NMR analysis (Figure 4B). Repaglinide did not reduce progres-
sive body weight loss (Figure 4C) or the number of HTT-enriched 
nuclear inclusions in the striatum, which were similar in DMSO- 
and repaglinide-treated R6/2 mice (Supplemental Figure 8A). In 
these experiments, correct drug intake was monitored periodi-
cally by testing reduced postprandial increase in blood glucose 
levels after fasting (Supplemental Figure 8B). Chronic gliben-
clamide administration did not affect HD symptoms in R6/2 mice, 
study showed that repaglinide, a drug commonly used to stimulate 
insulin secretion, binds specifically to NCS and blocks NCS activity 
(32). In the second study, binding of a diaryl-urea derivative (CL-888) 
to KChIP1 disrupted KChIP-1 activity on Kv4.3 channel function (33).
Since binding to recombinant DREAM was not evaluated 
directly in those studies, we used affinity pull-down and surface 
plasmon resonance experiments to test binding to DREAM. In 
both experiments, repaglinide or CL-888 binding to glutathione 
S-transferase–DREAM (GST-DREAM) was compared with bind-
ing to GST alone (negative control) and to GST-neurocalcin, an 
NCS (positive control) (32). In affinity pull-down, both repaglinide 
and CL-888 bound GST-DREAM and GST-neurocalcin in a Ca2+-
dependent manner (Figure 3A). Surface plasmon resonance 
confirmed these results and showed that repaglinide binds GST-
DREAM with higher affinity than does CL-888 (Figure 3B).
Binding of CL-888 or repaglinide to DREAM counteracted the 
DREAM effect on A-type potassium currents, reducing peak cur-
rent amplitude and accelerating inactivation kinetics (Figure 3, 
C and D). The IC50 values for this inhibition were 23.2 ± 13.9 and 
15.8 ± 9.5 nM for CL-888 and repaglinide, respectively (Figure 3C). 
As also reported for CL-888 and KChIP1 (33), neither molecule 
altered recovery from inactivation kinetics or the voltage depen-
dency of inactivation (Figure 3D) and both molecules blocked 
A-type current through Kv4.3 channels alone to a lesser extent 
than in the presence of DREAM (Supplemental Figure 6). Gliben-
clamide, used as a negative control, had no effect on A-type current 
amplitude or kinetics (Figure 3D). Repaglinide binding to recom-
binant DREAM, nonetheless, did not modify DREAM binding to 
Figure 3. Repaglinide binds to DREAM and blocks 
DREAM activity on potassium channel gating. (A) 
Affinity pull-down assay of recombinant GST, GST-
DREAM, or GST-neurocalcin (2% input in lanes 1–3). 
For each recombinant protein, the binding signal is 
shown to uncoupled Sepharose (lane 4), or to Sep-
harose coupled to (i) repaglinide with 4 mM EGTA 
(lane 5) or with 4 mM Ca2+ (lane 6) and (ii) other ben-
zoic acid derivatives (lanes 7–9; cyanic acid, aspirin, 
and 3,4,5-trimethyoxybenzoic acid, respectively). A 
representative blot is shown. (B) Surface plasmon 
resonance analysis of the binding of repaglinide 
(RP), CL-888, and glibenclamide (Glib) (all at 2 μM) 
to immobilized GST-DREAM. A representative curve 
is shown. (C and D) Effects of repaglinide, CL-888, or 
glibenclamide on Kv4.3 channel gating. (C) Concen-
tration curve for the inhibitory effect of repaglinide 
or CL-888. Experiments in CHO cells transfected 
with Kv4.3 and DREAM. Blockade was measured as 
the reduction in the amount of charge crossing the 
cell membrane (estimated from the integral of the 
current signal) during the 250 ms pulses to +60 mV. 
Lines represent the fit of the data to a Hill equation. 
Each point represents mean ± SEM of 3 to 9 experi-
ments. (D) Representative Kv4.3+DREAM currents 
recorded on transiently transfected CHO cells. 
Current traces were obtained after depolarization to 
+60 mV from a holding potential of 80 mV. Currents 
were recorded in control conditions and after perfu-
sion with 5 μM glibenclamide (left), 100 nM CL-888 
(center), or 100 nM repaglinide (right).
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Coimmunoprecipitation experiments with STHdhQ7/7 cells 
confirmed interaction between endogenous DREAM and ATF6 
(Figure 5A). This interaction was potentiated by Ca2+ and was 
reduced in the presence of repaglinide (Figure 5A). Pull-down 
assays corroborated the Ca2+ effect on the DREAM-ATF6 inter-
action and showed that Mg2+ binding to the second EF-hand in 
DREAM (37) did not increase the interaction with ATF6 (Figure 
5B). Pull-down assays also showed that the N-terminal part of 
DREAM (aa 1–90) and the N-terminal region of ATF6 (aa 1–376) 
interact in a repaglinide-dependent manner (Figure 5C). These 
results suggest that the DREAM-ATF6 interaction is involved in 
repaglinide-mediated neuroprotection.
To study a derepression mechanism, we evaluated the repa-
glinide effect on ATF6-dependent transcription using a reporter 
plasmid containing 5 ATF6-binding sites (p5×ATF6-GL3) (38). 
Induction of ER stress with tunicamycin increased reporter activ-
ity in STHdhQ7/7 cells (Figure 5D). Repaglinide exposure slightly 
increased basal, but markedly increased tunicamycin-induced, 
luciferase activity (Figure 5D). To link the effect of repaglinide 
on ATF6 transactivation with DREAM-mediated derepression, 
we conducted similar reporter assays in HeLa cells, which do 
not express DREAM. Exposure of HeLa cells to tunicamycin 
greatly increased luciferase activity, which was unaffected by 
repaglinide (Figure 5E). DREAM overexpression in HeLa cells 
reduced basal and tunicamycin-induced luciferase activity, and 
repaglinide largely counteracted this DREAM effect on reporter 
in agreement with previous studies (34) and with its inability to 
interact with DREAM. These results support DREAM potential 
as a therapeutic target in HD and identify DREAM-binding mol-
ecules as prospective drugs to ameliorate HD symptoms.
To further characterize the repaglinide effect on DREAM, we 
evaluated repaglinide treatment in STHdhQ111/111 cells sensitized 
to oxidative stress by DREAM overexpression. Exposure to repa-
glinide decreased H2O2- or rotenone-induced LDH release from 
sensitized STHdhQ111/111 cells (Figure 4D). Also, in these experi-
ments, CL-888 (IC50 183 nM) was less potent than repaglinide 
(IC50 88.8 nM) (Figure 4E). Similar protection by repaglinide (IC50 
30.7 nM) was obtained when disruption of mitochondrial trans-
membrane potential was used as an index of cell death after H2O2 
exposure (Supplemental Figure 9).
Derepression of ATF6 transcription mediates DREAM-related 
neuroprotection in HD. To define the mechanism of the neuropro-
tective effect of reduced DREAM function in HD, we focused on 
the interaction between GST-DREAM and the bZIP-containing 
transcription factor ATF6 (J.R. Naranjo, unpublished results), 
identified as a DREAM-interacting protein in nucleic acid–pro-
grammable protein arrays (NAPPA) (35). Since DREAM interacts 
with the bZIP protein cAMP responsive element binding protein 
(CREB) and this interaction abolishes CREB-dependent transacti-
vation (36), we hypothesized that DREAM downregulation in HD 
neurons might derepress ATF6 and promote ATF6-dependent 
transcription as well as UPR-dependent survival.
Figure 4. Repaglinide ameliorates the HD phenotype. 
(A) Latency to fall in the rotarod test of mice of the indi-
cated genotypes and age, exposed chronically to vehicle 
(DMSO) or repaglinide. DMSO-treated R6/2 mice were 
significantly different from WT controls at all ages, and 
repaglinide-treated R6/2 differed from repaglinide-
treated WT mice at all ages except at 17 weeks, when 
there was only a slight, nonsignificant improvement. 
***P < 0.001, ****P < 0.0001 vs. WT; #P < 0.05,  
###P < 0.001 vs. R6/2 (2-way ANOVA, Sidak’s post test; 
n = 13–17). (B) Nuclear magnetic resonance analysis 
of striatal volume in 18-week-old mice of indicated 
genotypes. *P < 0.0159, WT-DMSO vs. R6/2-DMSO; 
#P < 0.0303, R6/2-DMSO vs. R6/2-repaglinide (Mann 
Whitney U test; n = 4–7). (C) Body weight progression 
in male mice of the indicated genotypes exposed to 
DMSO or repaglinide. No significant differences (2-way 
ANOVA, Tukey’s multiple comparison test) were found 
within groups of untreated or repaglinide-treated mice 
(n = 10). (D) Cell death, as a percentage of maximum 
LDH released by DREAM-expressing STHdhQ111/111 cells. 
Cells were exposed to vehicle or repaglinide (100 nM) 
and stimulated with H2O2 (10 μM) or rotenone (100 nM). 
Data from 3 (rotenone) or 7 (H2O2) independent experi-
ments in quadruplicate were analyzed by 2-way ANOVA 
followed by Tukey’s test. ****P < 0.0001. (E) Effect of 
repaglinide on LDH release from N2a neuroblastoma 
cells (n = 4) after H2O2 exposure (20 μM). A 4-parameter 
(variable slope) nonlinear curve fitting resulted in an IC50 
of 88.79 ± 1.39 nM for repaglinide.
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activity (Figure 5E). To confirm a derepression mechanism, we 
analyzed directly the repaglinide effect on the expression of ATF6 
target genes. Thapsigargin-induced ER stress in STHdhQ7/7 cells 
increased mRNA levels of the ATF6 downstream targets XBP1, 
BIP, CHOP, and calreticulin (Figure 5, F and G, and Supplemen-
tal Figure 10), as observed in other cells (39–42). STHdhQ7/7 cell 
exposure to repaglinide had no effect on basal conditions, but sig-
nificantly increased thapsigargin-induced expression of ATF6 tar-
get genes (Figure 5, F and G, and Supplemental Figure 10).
Repaglinide activates ATF6 processing and redistribution in 
striatal neurons in R6/1 mice. Increased ATF6 transcription in the 
presence of repaglinide might be linked to an increase in Nt-ATF6 
processing and/or in DNA binding. Retardation assays nonethe-
less showed that DREAM-ATF6 interaction does not directly affect 
ATF6 binding to DNA in vitro (Supplemental Figure 11). Processing 
of ATF6 to the nuclear form involves protein-protein interactions 
and the sequential action of 2 proteases (3). We analyzed the effect 
of repaglinide on ATF6 processing in basal conditions and after 
tunicamycin stimulation. In whole-cell extracts of STHdhQ7/7 cells, 
basal Nt-ATF6 levels were low (Figure 6A), as reported for other 
cells (39, 43, 44). Repaglinide or tunicamycin exposure slightly 
increased Nt-ATF6 levels in STHdhQ7/7 cells; however, when both 
compounds were present, we observed a substantial increase in 
ATF6 processing, with a reduction in full-length ATF6 and a cor-
responding increase in Nt-ATF6 (Figure 6A). Analysis of nuclear 
extracts from STHdhQ7/7 cells exposed to repaglinide and tunica-
mycin showed a 4-fold increase in Nt-ATF6 compared with basal 
levels in untreated cells (Figure 6B and Supplemental Figure 12).
Figure 5. Repaglinide blocks DREAM-ATF6 interaction and regulates derepression of ATF6 targets. (A) Coimmunoprecipitation of endogenous ATF6 and 
DREAM proteins in STHdhQ7/7 cell lysates. Immunoprecipitated band (arrowhead) corresponds to full-length ATF6. Coimmunoprecipitation was performed in 
the absence or presence of Ca2+ (2 mM) and/or repaglinide (200 nM). Bottom, optical density of the ATF6 band from 3 independent immunoprecipitations is 
shown as mean relative intensity to the immunoprecipitate in the absence of Ca2+. (B) Pull-down using GST (–) and GST-DREAM1-256 (+) proteins as bait and in 
vitro–translated Nt-ATF61–376 as target in the presence of EGTA, Mg
2+, or Ca2+ (2 mM). The experiment was repeated twice. (C) Pull-down in the presence of Ca2+ 
using GST (–), GST-DREAM1–256 (D), or N-terminal GST-DREAM1–90 (ΔD) proteins as bait and in vitro–translated Nt-ATF61–376 as target, alone or with repaglinide 
(200 nM). b, empty beads. The experiment was repeated twice. Input for B and C was 3%. (D) Luciferase reporter assays in STHdhQ7/7 cells transiently trans-
fected with reporter plasmid p5×ATF6-GL3 and stimulated with tunicamycin (T) (200 ng/ml) alone or with repaglinide (100 nM). *P < 0.05, ***P < 0.001, vs. 
control; ###P < 0.001 for tunicamycin-stimulated cells alone or with repaglinide (1-way ANOVA, Bonferroni’s post-test). (E) Luciferase reporter assay in WT 
or DREAM-overexpressing HeLa cells stimulated as in C. ####P < 0.0001, tunicamycin-stimulated HeLa cells alone and with DREAM; #P < 0.05, tunicamycin-
stimulated DREAM-expressing HeLa cells alone or with repaglinide (1-way ANOVA, Bonferroni’s post-test). (F and G) Real-time qPCR analysis of XBP1 and 
BIP mRNAs after stimulation (14 hours) with thapsigargin (Tg) (200 nM) of STHdhQ7/7 cells alone or with repaglinide (200 nM; 1 hour). Values are normalized 
relative to HPRT mRNA levels. The experiment was repeated 3 times in triplicate. Significant differences were determined as in D: **P < 0.01, ****P < 0.0001, 
vs. control; #P < 0.05, ####P < 0.0001 for thapsigargin-stimulated cells alone or with repaglinide (1-way ANOVA, Bonferroni’s post-test).
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We sought evidence of an effect in vivo after chronic admin-
istration of repaglinide to mice. In immunohistochemistry experi-
ments, ATF6 immunoreactivity in striatal neurons from WT mice 
appeared as a diffuse staining (Figure 6C). This distribution was 
similar in WT mice receiving vehicle or repaglinide in the drink-
ing water (Figure 6C). In R6/2 mice, however, ATF6 immuno-
reactivity appeared as a large and dense intracellular aggregate 
(Figure 6C), an aberrant distribution first reported in R6/1 striatal 
neurons (13). Administration of repaglinide to R6/2 mice reduced 
the size of ATF6 aggregates (Figure 6C) and restored a more dif-
fuse cellular labeling, similar to WT neurons (Figure 6C). Western 
blot analysis of nuclear extracts from R6/1 mice showed reduced 
Nt-ATF6 levels in R6/1 compared with WT striatum (Figure 6D 
and Supplemental Figure 12), as described (13). Chronic admin-
istration of repaglinide did not affect nuclear Nt-ATF6 in WT 
mice, but significantly enhanced Nt-ATF6 levels in treated R6/1 
mice (Figure 6D and Supplemental Figure 12). Repaglinide thus 
increased the levels of transcriptionally active Nt-ATF6, which 
may contribute to enhanced ATF6-dependent transcription. 
Quantitative PCR (qPCR) analysis of mouse striatum showed 
decreased levels of Bip mRNA, an ATF6 target gene, in R6/1 com-
pared with WT mice (Figure 6E). Administration of repaglinide to 
R6/1 mice partially reversed the decrease in BiP expression and 
restored levels of Bip mRNA that were not significantly different 
from WT values (Figure 6E).
These results indicate that DREAM regulates ATF6 process-
ing and prosurvival UPR activity. Early neuroprotection in HD 
neurons is associated with a decrease in DREAM levels and can be 
potentiated by repaglinide administration.
Discussion
Most neurodegenerative diseases of genetic origin are slow-devel-
oping pathologies that manifest symptoms years after neuronal 
dysfunction has begun. A plausible reason for this delayed onset is 
early activation of endogenous neuroprotective mechanisms that 
temporarily maintain neuron function in a genetically unfavor-
able environment. We propose that reduction of DREAM activity, 
which leads to ATF6 derepression and improved prosurvival UPR, 
Figure 6. Repaglinide activates ATF6 processing in mouse striatal neurons. (A) Western blot analysis of whole-cell extracts from STHdhQ7/7 cells stimu-
lated with tunicamycin (200 ng/ml) and repaglinide (100 nM) alone or in combination. Migration of full-length ATF6 (Fl-ATF6) and the N-terminal ATF6 
(Nt-ATF6) are shown. Asterisk marks a nonspecific band. Loading control with nonphosphorylated ERK is shown below. The relative ratio of Nt-ATF6 to 
Fl-ATF6 after scanning is shown (below). (B) Western blot analysis of nuclear extracts from STHdhQ7/7 cells stimulated as in A. After normalizing to the 
loading control (lamin A/C), optical density of Nt-ATF6 bands relative to control untreated cells is shown (below). (C) Immunohistochemistry for ATF6 in 
striatal neurons from WT and R6/2 mice receiving DMSO or repaglinide. A diffuse intracellular ATF6 labeling is observed in WT neurons. In striatal neurons 
from DMSO-treated R6/2 mice, ATF6 immunoreactivity appears as a dense intracellular aggregate (arrows). In repaglinide-treated R6/2 mice, ATF6 label-
ing has a diffuse distribution, similar to WT neurons. Scale bar: 20 μm. (D) Western blot analysis of nuclear extracts from striatum from WT and R6/1 mice 
receiving DMSO (–) or repaglinide. A representative autoradiogram is shown. After quantification of the autoradiograms, ratios vs. loading control TBP 
were normalized to DMSO-treated WT mice for each experiment. **P < 0.01, R6/1 vs. WT; #P < 0.05, R6/1 vs. repaglinide-treated R6/1 mice (1-way ANOVA 
[Kruskal-Wallis], followed by Dunn’s multiple comparisons test, n = 6 mice in each group). (E) Real-time qPCR analysis of Bip mRNA in the striatum from 
WT and R6/1 mice receiving DMSO (–) or repaglinide, as indicated. Values are normalized relative to Hprt mRNA levels. ***P < 0.001, DMSO-treated R6/1 
vs. WT; #P < 0.05, R6/1 vs. RP-treated R6/1 mice (statistics as in D, n = 7 mice in each group).
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amelioration in R6/1 mice, a mouse model better suited for that 
purpose. At the molecular level, we show that repaglinide binding 
to DREAM does not affect its interaction with DNA, but blocks the 
DREAM-mediated increase in A-type currents, reduces sensitiza-
tion to oxidative stress, and disrupts the DREAM-ATF6 interaction 
to enhance ATF6 nuclear accumulation and expression of ATF6 
target genes. Our in vivo results support the idea that repaglinide 
potentiates the UPR under ER stress, i.e., in R6/1 mice, and does 
not alter ATF6 processing in striatal neurons in WT mice. Identi-
fication of DREAM-binding molecules with greater affinity and/
or selectivity might improve therapeutic effectiveness in delaying 
disease onset and ameliorating symptoms in HD patients.
Increased nuclear accumulation of ATF6 and expression of its 
target genes was described in ob/ob mice after chronic adminis-
tration of the chemical chaperones 4-phenyl-butyric acid (4-PBA) 
(8) and taurine-ursodeoxycholic acid (TUDCA) (50). The mecha-
nisms that link protein stabilization by chemical chaperones with 
ATF6 processing have not been identified; whether these com-
pounds bind to DREAM or interfere with the DREAM/ATF6 inter-
action is also not known. Future studies will determine whether 
chemical chaperones modify onset and progression of disease 
symptoms in mouse HD models.
In conclusion, our results identify early DREAM downregu-
lation in HD, which promotes neuroprotection via derepression 
of ATF6 signaling and activation of prosurvival UPR activity. We 
found that pharmacological inhibition of DREAM activity also 
induces UPR function, which opens a new avenue for therapeutic 
intervention in HD patients.
Methods
Mice and in vivo treatment. R6/2 and R6/1 mice were originally from 
Jackson Laboratories. Our colonies were maintained by breeding R6 
mice with CBA × C57BL/6 mice to obtain heterozygous mutants and 
WT offspring. Genotype and CAG-repeat length were determined by 
PCR-based amplification using genomic DNA extracted from tail biop-
sies. In R6/2 mice, the repeat length in the mutant transgene increased 
with successive crossings. Only R6/2 mice with fewer than 200 CAG 
repeats were used in these experiments. Homozygous DREAM knock-
out mice (27) or transgenic mice expressing dominant active mutant 
DREAM (21, 26), both in the CBA × C57BL/6 hybrid background, were 
crossed with R6/2 or R6/1 mice to generate R6/2 DREAM+/– and R6/1 
daDREAM mice, respectively.
Repaglinide (2 μg/ml) or vehicle (DMSO, 0.2 μl/ml) was admin-
istered chronically in drinking water shortly after weaning. Four i.p. 
injections of 3-NPA (60, 60, 80, 80 mg/kg) were given, 1 every 12 
hours, and motor skills on the rotarod were monitored 1 hour after 
each injection. For life span analysis, mice were monitored twice daily 
from 10 weeks of age until the end of the experiment. Death dates of 
R6/2 and R6/2 DREAM+/– mice were recorded; no natural deaths were 
observed for WT or DREAM+/– mice in this period.
Behavioral analysis. Experiments were performed in adult R6/2 
mice and WT littermates. Mice were initially housed 5 per cage in a 
temperature-controlled (21 ± 1°C) and humidity-controlled (65% ± 
10%) room with a 12-hour light/12-hour dark cycle (lights on from 
0800 to 2000 hours), with food and water ad libitum. All experiments 
took place during the light phase. All behavioral experiments were car-
ried out in blind conditions.
is one of these neuroprotective mechanisms. The contribution of 
other molecular mechanisms to the neuroprotective action follow-
ing DREAM downregulation in HD cannot be excluded.
Neurodegenerative diseases are associated with accumula-
tion of intracellular protein aggregates; the importance of defec-
tive UPR in these pathologies is increasingly recognized (5, 10, 
12). Reduced ATF6 activity is reported in amyotrophic lateral 
sclerosis type VIII, a disease produced by a single mutation in ves-
icle-associated membrane protein–associated protein B (VAPB) 
that increases its ability to interact with ATF6 and block ATF6 
transcription (45). Decreased ATF6 processing and nuclear accu-
mulation of the transcriptionally active Nt-ATF6 fragment was 
also reported in the striatum of R6 mice and of HD patients (13). 
That study showed a decrease in active ATF6 in young mice well 
before neurological symptoms appeared, similar to our results for 
DREAM expression.
The interaction between DREAM and ATF6 further suggests 
a link between these 2 early molecular events. Reduced DREAM 
levels derepress ATF6 activity and partially compensate for low 
ATF6 transcriptional activity in HD neurons. ATF6 target genes 
participate in the protein refolding and have antiapoptotic activ-
ity (3), which supports a neuroprotective mechanism related to 
the decrease in DREAM protein. Following UPR stimulation, 
ATF6 forms multiprotein complexes with XBP1 and NF-Y to 
activate transcription of target genes, for instance, to induce 
components of the ER-associated degradation pathway (ERAD) 
(41, 46). It is not known whether DREAM regulates Nt-ATF6 
interaction with these nucleoproteins and thus modifies ATF6-
dependent transcription. Ca2+ enhances DREAM-ATF6 interac-
tion. Internal Ca2+ mobilization, e.g., with thapsigargin, activates 
ATF6 processing; the Ca2+-dependent interaction with DREAM 
suggests a feedback mechanism that terminates ATF6 activation 
in physiological conditions.
A defective UPR is a common feature in diabetes and neuro-
degenerative diseases. Diabetes is associated with several neu-
rodegenerative diseases, including Parkinson disease, Alzheimer 
disease, and HD and might contribute to some of the neurologi-
cal symptoms (47). R6/2 mice reproduced the diabetes phenotype 
(48), and abnormal glucose use is linked to progressive reduction 
in insulin release (34). These observations prompted several stud-
ies of hypoglycemic drugs for HD treatment. Glibenclamide and 
rosiglitazone, 2 oral hypoglycemic agents commonly used to treat 
diabetic patients, were tested in R6/2 mice. After chronic treat-
ment, neither drug improved survival, weight loss, or motor coor-
dination, although glibenclamide had an acute positive effect on 
glucose levels (34). These results supported previous studies in 
R6/2 mice, which showed that vaccination against murine HTT 
improves the diabetic phenotype, with no effect on body weight, 
progression of motor symptoms, or neuropathology (49). Here, 
we show that chronic administration of repaglinide, but not glib-
enclamide, delays onset and progression of disease symptoms in 
R6/2 mice. The effect of repaglinide administration or induced 
DREAM haplodeficiency on cognitive impairment in R6/2 mice 
was not analyzed in this study. Since changes in DREAM activity 
are associated with modified long-term potentiation (LTP) and 
long-term depression (LTD) (20, 26), future studies will analyze 
the potential effect of DREAM-binding molecules in cognition 
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sure to the toxin by measuring LDH release to medium using the 
Cytotoxicity Detection kit (Clontech) or by analyzing the disruption of 
mitochondrial transmembrane potential with the MitoCapture Mito-
chondrial Apoptosis Detection Fluorimetric Kit (BioVision). Cell cul-
tures were routinely checked for mycoplasma infection.
Immunohistochemistry. WT and R6/1 mice were fixed by transcar-
dial perfusion with 4% paraformaldehyde (PFA) (pH 7.4) under deep 
pentobarbital anesthesia. The brains were dissected and post-fixed in 
PFA overnight, rinsed, and further incubated in 20% sucrose in 0.1 M 
PBS. Brains were sectioned on a cryo-microtome. For DREAM staining, 
sections were rinsed 3 times with PBS and incubated (overnight, room 
temperature) with polyclonal rabbit anti-DREAM (Ab1014, 1:20; ref. 
28), followed by Cy3-conjugated secondary antibodies (1:200, Jackson 
Laboratories) (2 hours, room temperature). Samples were imaged and 
analyzed with a Nikon Eclipse microscope. For ATF6 staining, sections 
were incubated with rabbit polyclonal anti-ATF6 (H-280, Santa Cruz 
Biotechnology Inc.) and developed with Vectastain Elite ABC Kit (Dako).
Mutant huntingtin immunoreactive inclusions (anti-HTT, MAB-
5374, Millipore) were counted in 5-μm cryostat sections of a coro-
nal midstriatal level of mouse brain, and each animal was assessed 
in a single section. A 0.15-mm2 rectangular area (0.5 × 0.3 mm) was 
defined at 1 striatum and was divided in 2 separate subareas compris-
ing 20 sections each. Positive inclusions in 10 square sections in each 
subarea were counted. A final average count was obtained by calcu-
lating the average counts of both 20-section subareas. Final data are 
expressed as positive inclusions per mm2.
Western blot. STHdhQ cells were lysed in lysis buffer (50 mM 
Tris HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.5% 
deoxycholate, 0.1% SDS) supplemented with a protease inhibitor 
cocktail (Roche); cell pellets were incubated on ice in lysis buffer for 45 
minutes, with occasional vortexing. Nuclear extracts from STHdhQ7/7 
cells and mouse striatal tissue were prepared using NE-PER Nuclear 
and Cytoplasmic Extraction Reagents (Pierce). To prepare total stria-
tal extracts, mouse and human striatal tissues were homogenized on 
ice in RIPA buffer (9806, Cell Signaling Technology) supplemented 
with 1 mM PMSF. Extracts were cleared by centrifugation (14,000 g, 
20 minutes). Samples (20–30 μg) were analyzed by SDS-PAGE and 
immunoblot. PVDF membranes were incubated overnight at 4°C with 
the following specific antibodies: anti-DREAM (Ab730, ref. 51, or 1B1, 
ref. 36), ATF6α (H-280, Santa Cruz Biotechnology, Inc.), and as con-
trols, with ERK1/2 (MK12, Millipore), α-tubulin (DM1A, Millipore), 
PI3K p85b (52), TBP (MAB3658, Millipore), CREB (06-863, Milli-
pore), or lamin A/C (MAB636, ThermoFisher). Secondary antibod-
ies used were HRP-conjugated donkey anti-rabbit or anti-mouse IgG 
(Jackson ImmunoResearch; 1 hour, room temperature), and signals 
were detected with ECL (SuperSignal West Femto, Thermo Scientific 
or ECL Select, GE Healthcare). Band intensity was quantified with 
QuantityOne software (Bio-Rad).
Coimmunoprecipitation. DREAM and ATF6 were coimmunopre-
cipitated from whole-cell extracts (300 μg) from STHdhQ7/7 cells, incu-
bated with 0.5 μg affinity-purified rabbit anti-DREAM Ab1014 (28), 
with addition of calcium (2 mM) or repaglinide (400 nM) to the whole-
cell extract where appropriate. Samples were immunoblotted with rab-
bit anti-ATF6α (H-280, Santa Cruz Biotechnology Inc.) and proteins 
visualized with HRP-conjugated secondary antibody (Jackson Immu-
noResearch) followed by ECL (ECL Select). Blots were quantified using 
Quantity One software (Bio-Rad).
The footprint test was used to compare the gait of R6/2 transgenic 
with that of WT control mice. To obtain footprints, mouse hind and 
forepaws were coated with blue and red nontoxic paints, respective-
ly. Mice were then allowed to walk twice along a 40-cm long, 6-cm 
wide runway cylinder (with 6-cm high walls) into an enclosed box. A 
fresh sheet of white paper was placed on the runway floor for each run. 
Footprint patterns were analyzed using 2-step parameters. Hind and 
front-base width were each measured as the mean distance between 
left and right hind footprints and left and right front footprints, respec-
tively. These values were determined by measuring the perpendicular 
distance of a given step to a line connecting its preceding and posterior 
steps. For each step parameter, 3 values were measured from each run, 
excluding footprints made at the beginning and end. The mean value 
of each set of 3 values was used in subsequent analyses.
The rotarod test was used to measure motor coordination and 
balance (Accelerating Model, Ugo Basile, Biological Research Appara-
tus). For basal rotarod performance, mice were tested on 2 consecu-
tive days. On day 1 (training), each mouse was placed on the rotarod 
at a constant speed (4 rpm) for a maximum of 60 seconds. The proce-
dure was repeated 3 times, with a rest period of 30 minutes between 
trials. On day 2 (experiment), mice received 1 training trial at constant 
speed (4 rpm) for a maximum of 60 seconds, followed by 3 test trials 
with acceleration from 4 to 40 rpm over a period of 60 seconds. The 
latency to fall off the rotarod within this time period was recorded. Any 
mice remaining on the apparatus after 60 seconds were removed and 
their time scored as 60 seconds. Data from the 3 test trials were aver-
aged for each animal and used in statistical analyses.
Nuclear magnetic resonance. Striatal volume was calculated by 
magnetic resonance imaging. Experiments were performed at the 
Nuclear Magnetic Resonance Centre (Universidad Complutense, 
Madrid, Spain) using a BIOSPEC BMT 47/40 (Bruker) operating at 4.7 
T and equipped with a 12-cm actively shielded gradient system. Mice 
were anesthetized with oxygen/isofluorane and placed in prone posi-
tion inside a cradle. The head was immobilized and placed beneath 
a 4-cm surface coil. Mice were monitored using a respiration sen-
sor. Global shimmer was assessed, after which 3 gradient-echo scout 
images in axial, sagittal, and coronal directions were acquired (time 
to repetition/echo time = 100/3.2 ms, matrix = 128 × 128). A 3D fast 
spin-echo experiment with axial slice orientation was performed using 
the following acquisition parameters: time to repetition = 3,000 ms, 
effective echo time = 86.5 ms, number of averages = 2, field of view = 
2.56 × 2.56 × 1.28 cm3, matrix size = 256 × 128 × 32. The reconstructed 
matrix size was 256 × 256 × 32. Total acquisition time was 27 minutes.
Human postmortem brain tissue. Putamen samples from HD 
patients and age-matched controls were obtained from the Banco de 
Tejidos de la Fundacion CIEN (Madrid, Spain), following the ethical 
guidelines of the Declaration of Helsinki. Case information can be 
found in Supplemental Table 1.
Cells and cell viability. STHdhQ knockin striatal neurons (30) were 
obtained from J.J. Lucas (Centro de Biología Molecular–CSIC, Madrid, 
Spain). N2a mouse neuroblastoma, HEK293, CHO, and HeLa cells 
were from ATCC. All cells were cultured in DMEM (with 10% FBS, 
penicillin/streptomycin, and Glutamax; all from Invitrogen). STHdhQ 
knockin striatal neurons were maintained at 32°C. Cells were treated 
with repaglinide at indicated concentrations 30 minutes before expo-
sure to the mitochondrial toxins H2O2 (10 μM), rotenone (100 nM), or 
staurosporine (5 nM). Cell viability was assessed 3 hours after expo-
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μg/ml in acetate buffer, pH 4, and immobilized to the sensor chip 
by amine coupling. The surface was activated by injecting a solution 
of 0.2 M N-ethyl-N-dimethylaminopropyl-carbodiimide (EDC) and 
50 mM N-hydroxysuccinimide (NHS) for 7 minutes. GST-DREAM 
or GST-neurocalcin was injected for 7 minutes and the surface was 
blocked by injecting 1 M ethanolamine at pH 8.5 for 7 minutes. The 
final immobilization level was 6,900 resonance units (RU) for GST-
DREAM and 7,500 RU for GST-neurocalcin. Immobilization was fol-
lowed by several washes with DMSO running buffer (50 mM Tris, 
pH 7.5, 50 mM NaCl, 2 mM CaCl2 with 2% DMSO and 0.05% Tween 
X100) to equilibrate the protein surface. Unmodified dextran was 
used as a reference surface. Compounds were injected over the ref-
erence and protein flow cells for 1 minute at a flow rate of 90 μl/min. 
Each cycle consisted of a 1-minute waiting period to monitor base-
line stability, a 1-minute injection of compound, a 1-minute undis-
turbed dissociation phase, and a wash of the flow system with a 1:1 
mixture of DMSO and running buffer.
Electrophysiology. Electrophysiological experiments were per-
formed in CHO cells transiently transfected with cDNA encoding 
Kv4.3 or Kv4.3 plus DREAM (KChIP3) and reporter plasmid CD8. 
Cells were cultured at 37°C in Iscove’s medium supplemented with 
10% FBS, 1% l-glutamine, and 1% penicillin-streptomycin in 5% CO2. 
Transient transfection was performed with Fugene 6 (Roche). Before 
experimental use, cells were incubated with polystyrene microbeads 
precoated with anti-CD8 antibody (Dynabeads M450; Dynal).
Potassium currents were recorded at room temperature 
(20°C–22°C) using the whole-cell patch-clamp technique with an 
Axopatch 200B patch-clamp amplifier (Molecular Devices). Currents 
were filtered at 2 kHz (4-pole Bessel filter) and sampled at 4 kHz. 
Micropipettes were pulled from borosilicate glass capillary tubes (Nar-
ishige GD-1) on a programmable horizontal puller (Sutter Instrument 
Co.) and heat polished with a microforge (Narishige). Micropipette 
resistance was 1.8-3 MΩ. Capacitance and series resistance compen-
sation were optimized, with 80% compensation of the effective access 
resistance usually obtained. The intracellular pipette-filling solution 
contained 80 mM K-aspartate, 42 mM KCl, 3 mM phosphocreatine, 
10 mM KH2PO4, 3 mM MgATP, 5 mM HEPES-K, and 5 mM EGTA and 
was adjusted to pH 7.25 with KOH. The bath solution contained 136 
mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM HEPES-Na, 
and 10 mM glucose and was adjusted to pH 7.40 with NaOH.
Real-time qPCR. RNA was isolated from tissues or cell suspen-
sions using TRIzol, treated with DNase (Ambion), and reverse tran-
scribed using hexamer primer and Moloney murine leukemia virus 
reverse transcriptase. To confirm the absence of genomic DNA, 
each sample was processed in parallel without reverse transcrip-
tase. Real-time qPCR for endogenous DREAM was performed as 
described (28). Assays from Applied Biosystems were used for the 
DREAM target genes c-fos (Mm00487425_m1), Junb (Mm00492781_
m1), and Mef2c (Mm0122839_m1) and for the ATF6 target genes 
calreticulin (Mm00482936_m1), Xbp1 (Mm00457359_m1), and 
Chop (Mm00492097_m1). For Bip, the primers 5′-ACTTGGAAT-
GACCCTTCGGTG-3′ and 5′-TGCTTGTCGCTGGGCATC-3′ as 
well as SYBR technology were used. ATF6 target genes were quan-
tified by the normalized expression method using Hprt as a refer-
ence with primers 5′-TTGGATACAGGCCAGACTTTGTT-3′ and 
5′-CTGAAGTACTCATTATAGTCAAGGGCATA-3′ and the MGB 
probe 5′-TTGAAATTCCAGACAAGTTT-3′.
The interaction between DREAM and ATF6 was determined 
using NAPPA (Protoarray v5.0, Life Technologies) (J.R. Naranjo, data 
not shown). Arrays were hybridized with recombinant GST-DREAM or 
GST alone and developed using affinity-purified rabbit anti-DREAM 
(Ab1014; ref. 28). Arrays were scanned using an Axon GenePix 4100A 
microarray reader with the GenePixPro 6.0 program and results ana-
lyzed with Prospector software (Invitrogen). Z-scores were calculated 
to assess statistical significance according to the following formula: z = 
(x – μ)/σ where x is the raw value, μ the population mean, and σ the SD 
for the population. The Z-score for the DREAM-ATF6 interaction was 
5.6, above the cut-off value for statistical significance (Z-score ≥ 2).
Electrophoretic mobility shift analysis. Band-shift assays with Nt-
ATF6 (38) or DREAM (53) were performed as reported for respective 
recombinant protein.
Luciferase reporter assays. STHdhQ7/7 or HeLa cells (4 × 105 cells/p60 
mm plate) were transfected 3 hours after seeding using JetPEI (Polyplus 
Transfections), with 3 μg reporter plasmid p5×ATF6-GL3 (Addgene) 
per plate of STHdhQ7/7 cells. For HeLa cells, 0.5 μg reporter plasmid 
and 2.5 μg empty pcDNA3 or DREAM expression vector were used per 
plate. At 20 hours after transfection, cells were exposed to repaglinide 
or vehicle 1 hour before tunicamycin stimulation and harvested 14 hours 
later. Luciferase reporter assays were as described (21).
Affinity pull-down assay. Molecules were coupled to EAH Sepha-
rose (Pierce) resin according to the manufacturer’s protocol. Coupled 
resin samples and noncoupled control resin were blocked with 5% BSA 
in 20 mM Tris HCl, pH 7.5, and washed once with Tris buffer. Equi-
molar amounts of recombinant GST-DREAM or GST protein in 1 ml 
binding buffer (20 mM Tris HCl, pH 7.5, 150 mM NaCl, 4 mM CaCl2 or 
EGTA, Complete Mini EDTA-free protease inhibitors [Roche], 0.1% 
BSA) were added to 100 μl resin samples and incubated overnight at 
4°C on a rotating wheel. Samples were washed 3 times with wash buf-
fer (20 mM Tris HCl, pH 7.5, 500 mM NaCl, 4 mM CaCl2 or EGTA, 
Complete Mini EDTA-free protease inhibitors, 0.1% BSA) and twice 
with the same buffer without BSA. Proteins were eluted from the resin 
with 2× SDS sample buffer. Samples were analyzed by Western blot 
using anti–GST-HRP (Sigma-Aldrich, A-7340, 1:2000).
GST-protein pull-down. Equimolar amounts of GST, full-length 
GST-DREAM (aa 1–256), and amino terminal GST-DREAM (aa 1–90) 
recombinant proteins were bound to glutathione Sepharose beads 
(GEH) in binding buffer (PBS, 5 mM DTT, 1 mM EDTA, Complete Mini 
EDTA-free protease inhibitors [Roche]) for 2 hours with rotation at 4°C. 
After extensive washing with binding buffer, the beads were blocked 
with 5% BSA overnight at 4°C, washed with binding buffer, and recon-
stituted in pull-down buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 10% 
glycerol, 0.1% NP40, 5 mM DTT, Complete Mini EDTA-free protease 
inhibitors [Roche] supplemented with 2 mM CaCl2 or MgCl2 or EGTA). 
In vitro translated (TNT Quick Coupled Transcription/Translation, 
Promega) Nt-ATF6 (aa 1–376) was added to the beads, as well as repa-
glinide (400 nM) as indicated, and incubated (1 hour, with rotation at 
4°C). After extensive washing with pull-down buffer, bound protein 
was eluted with 2× SDS sample buffer and Western blot developed with 
an ATF6 antibody (H-280, Santa Cruz Biotechnology Inc.).
Surface plasmon resonance. The Biacore X100 was used to per-
form interaction analyses at 20°C. GST-DREAM or GST-neurocalcin 
were immobilized on a CM5 sensor chip consisting of a carboxy-
methyl-modified dextran polymer linked to a gold-covered glass 
support. GST-DREAM and GST-neurocalcin were diluted to 100 
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Gene-expression microarray. Whole striatum RNA from WT and 
transgenic mice was prepared using TRIzol (Invitrogen) and the 
RNAeasy Mini Kit (QIAGEN). RNA was quantified and quality was 
controlled with a 2100 Bioanalyzer (Agilent Technologies). cDNA was 
synthesized from 4 μg total RNA using 1-cycle target labeling and con-
trol reagents (Affymetrix) to produce biotin-labeled cRNA. The cRNA 
preparation (15 μg) was fragmented (94°C, 35 minutes) into 35–200 
bases in length. Labeled cRNAs were hybridized to Affymetrix oligo-
nucleotide arrays (GeneChip Mouse Genome 430 2.0 Array). Each 
sample was added to a hybridization solution containing 100 mM 
2-(N-morpholino) ethanesulfonic acid, 1 M Na+, and 20 mM EDTA 
with 0.01% Tween-20 to a final cRNA concentration of 0.05 μg/ml 
and hybridized (16 hours, 45°C). Each microarray was washed, stained 
with streptavidin-phycoerythrin in a Fluidics Station 450 (Affyme-
trix), and scanned at 1.56 μm resolution in a GeneChip Scanner 3000 
7G System (Affymetrix).
Microarray data analysis. Four biological replicates were hybrid-
ized independently for each transcriptomic comparison. GeneChip 
intensities were background corrected, normalized, and summarized 
by the RMA method (54) using the Affy package (55) from Bioconduc-
tor. After normalization, GeneChip probeSetIDs sharing the same 
gene symbol and gene title, according to the annotations provided by 
Affymetrix, were merged and their expression values were averaged. 
For each comparison, a moderated t test was applied to identify differ-
entially expressed genes as implemented in the Limma package (56) 
from Bioconductor. Raw P values were adjusted using the false dis-
covery rate (FDR) method (57). Genes with a FDR of less than 0.005 
were included in the list of induced (fold change > 0) or repressed (fold 
change < 0) candidates. The FIESTA viewer was used to select these 
numerical filters and the candidate genes in each comparison (http://
bioinfogp.cnb.csic.es/tools/FIESTA/index.php). The Venny tool was 
used to create Venn diagrams with all combinations of up- and down-
regulated genes in the 2 comparisons, R6/2 DREAM+/– versus WT and 
R6/2 versus WT (http://bioinfogp.cnb.csic.es/tools/venny/index.
html). GeneCodis (58) was used for functional enrichment analysis 
of relevant genes, where Molecular Function terms of the generic GO 
slim set were considered (Mundodi and Ireland; http://www.geneon-
tology.org/GO.slims.shtml).
Statistics. All data values are shown as mean ± SEM. Differences 
were considered significant at P < 0.05. Comparisons between groups 
were analyzed with 1- or 2-way ANOVA when appropriate, followed 
by multiple comparisons using the indicated post tests. In the case of 
small sample size or non-Gaussian distribution, nonparametric tests 
were used. Two-group comparisons were performed with unpaired 
2-tailed Student’s t test. Animal experiments were randomized. Sam-
ple size was not predetermined by statistical method. Prism GraphPad 
Software 6.0 was used to plot graphs and for statistical analysis.
Study approval. Behavioral tests and animal care were conducted 
in accordance with standard ethical guidelines (European Commu-
nities Directive 86/609 EEC; NIH 1995) and approved by the CNB-
CSIC ethical committee.
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